conflicts of interest as they apply to each member and consultant. FDA acknowledges that there may be potential conflicts of interest, but because of the general nature of the discussion before the committee, these potential conflicts are mitigated.
With respect to FDA's invited guests, Dr. Leonard Wartofsky reports that he has a consulting contract with Abbott Laboratories. Dr. Bo Olsson reports that he is employed full-time by AstraZeneca Pharmaceuticals in Sweden, and Dr. Rick Granneman reports he is employed full-time as Vice President, Center of Clinical Assessment, by Abbott Laboratories.
We would also like to disclose that Dr. Leon Shargel and Dr. Efraim Shek are participating in this meeting as acting industry representatives, acting on behalf of regulated industry. Dr. Shargel reports he is employed full-time by Eon Laboratories as Vice President, Biopharmaceutics. Dr. Shek reports holding stock in Abbott Laboratories and Cephalon, Incorporated, and is employed full-time as Divisional Vice President for Abbott Laboratories.
In the event that the discussions involve any